Momcozy and Peanut Partner for Mother’s Day to Champion Maternal Support
LOS ANGELES, April 29, 2025 /PRNewswire/ -- This Mother's Day, Momcozy, a global leader in maternal health, announces a meaningful...
Pregnancy
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming...
Digital Health Market Size to Reach $946.04 Billion by 2030 at CAGR 22.2% – Grand View Research, Inc.
SAN FRANCISCO, April 22, 2025 /PRNewswire/ -- The global digital health market size is expected to reach USD 946.04 billion by...
UCSF Expands Arrhythmia Research with Vivalink’s Biometrics Data Platform in Study to Examine Arrhythmias in High-Risk Pregnancies
BRITE-MOM study uses Vivalink's wearable devices and data platform to examine arrhythmias in high-risk pregnancies CAMPBELL, Calif., April 22, 2025...
Best Legal Steroids 2025: Natural Alternatives That Work For Bulking, Cutting & Muscle Growth By CrazyBulk
CrazyBulk CrazyBulk Madison Avenue, New York City, April 18, 2025 (GLOBE NEWSWIRE) -- Looking to take your bodybuilding game to...
Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism
CELEBRATION, Fla., April 17, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company...
Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2025
Highlights will include data from non-clinical and real-world patient useBOSTON, April 10, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a...
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting...
ON WORLD HEALTH DAY, MOODY LAUNCHES FIRST-EVER APP MODE TACKLING PREGNANCY LOSS AND MENTAL HEALTH
50% OF MATERNAL MENTAL HEALTH DISORDERS GO UNDIAGNOSED THE NEW MODE SUPPORTS MOTHERS THROUGH MENTAL HEALTH CRISIS, PREGNANCY & PREGNANCY...
MakeWell Announces Free Access to AI-Driven Healthcare Companion App in Recognition of the WHO’s World Health Day
SAVANNAH, Ga., April 7, 2025 /PRNewswire/ -- In honor of the annual World Health Day, MakeWell, a pioneering AI healthcare...
Vital Start Health Expands Access to VR-Based Pregnancy Support Tools on Pregnancy+
PHILADELPHIA--(BUSINESS WIRE)--#EAP--Vital Start Health is now offering direct access to its virtual reality programs and expert-backed resources for pregnancy support...
Meet vívoactive 6, the latest health and fitness smartwatch from Garmin
Know your body better with popular fitness, wellness and smart features—all on a bright, colorful display OLATHE, Kan., April 1,...
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities
Updates strengthen Certara’s position as a leader of PBPK modeling in drug development to advance regulatory decision-makingRADNOR, Pa., April 01,...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in...
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four...
THE MOM’S CHOICE AWARDS NAMES AI-POWERED PREGNANCY & BABY WELLNESS WEARABLE ‘ELORA’ AMONG THE BEST IN FAMILY-FRIENDLY PRODUCTS
DOVER, Del., March 25, 2025 /PRNewswire/ -- The Mom's Choice Awards® has named Elora*, from leading technology startup LittleOne.Care™, as among...
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) --...
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) --...
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in CanadaLONDON...
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved,...